BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 Life Science Investing
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Life Science Investing
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates Life Science Investing
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada Biotech Investing
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development Life Science Investing
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update Life Science Investing
PainReform's DeepSolar, Developing "DeepSolar Predict" within the NVIDIA Connect Program, Featured in The Market Link's "Watchlist Interview" and Announces Progress Toward Pilot Projects Life Science Investing
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results Life Science Investing
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 Life Science Investing
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases Biotech Investing
